Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Esophageal Cancer Treatment Pipeline Review H2 2016

Wednesday, October 19, 2016 23:21
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Esophageal Cancer – Pipeline Review, H2 2016’, provides an overview of the Esophageal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693289-esophageal-cancer-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer 
- The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects 
- The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Esophageal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693289-esophageal-cancer-pipeline-review-h2-2016            

Key points in table of content

Table of Contents 2 
List of Tables 5 
List of Figures 7 
Introduction 9 
Global Markets Direct Report Coverage 9 
Esophageal Cancer Overview 10 
Therapeutics Development 11 
Pipeline Products for Esophageal Cancer – Overview 11 
Pipeline Products for Esophageal Cancer – Comparative Analysis 12 
Esophageal Cancer – Therapeutics under Development by Companies 13 
Esophageal Cancer – Therapeutics under Investigation by Universities/Institutes 17 
Esophageal Cancer – Pipeline Products Glance 18 
Late Stage Products 18 
Clinical Stage Products 19 
Early Stage Products 20 
Esophageal Cancer – Products under Development by Companies 21 
Esophageal Cancer – Products under Investigation by Universities/Institutes 26 
Esophageal Cancer – Companies Involved in Therapeutics Development 27 
Adaptimmune Therapeutics Plc 27 
Advaxis, Inc. 28 
Advenchen Laboratories, LLC 29 
Almac Discovery Limited 30 
Amgen Inc. 31 
ArQule, Inc. 32 
Array BioPharma Inc. 33 
Aslan Pharmaceuticals Pte. Ltd. 34 
ATLAB Pharma SAS 35 
Bayer AG 36 
Betta Pharmaceuticals Co. Ltd. 37 
Boehringer Ingelheim GmbH 38 
Celgene Corporation 39 
Celldex Therapeutics, Inc. 40 
Cellectar Biosciences, Inc. 41 
Cerulean Pharma, Inc. 42 
Cyclacel Pharmaceuticals, Inc. 43 
F. Hoffmann-La Roche Ltd. 44 
Genmab A/S 45 
GlaxoSmithKline Plc 46 
Glycotope GmbH 47 
Hutchison MediPharma Limited 48 
Ignyta, Inc. 49 
ImmunoFrontier, Inc. 50 
Immunomedics, Inc. 51 
Johnson & Johnson 52 
Komipharm International Co., Ltd. 53 
MacroGenics, Inc. 54 
MaxiVAX SA 55 
Mebiopharm Co., Ltd. 56 
MedImmune, LLC 57 
Merck & Co., Inc. 58 
Mirna Therapeutics, Inc. 59 
Novartis AG 60 
Omeros Corporation 61 
Omnitura Therapeutics Inc. 62 
Oncolys BioPharma Inc 63 
OncoMed Pharmaceuticals, Inc. 64 
Ono Pharmaceutical Co., Ltd. 65 
Pfizer Inc. 66 
Proteo, Inc. 67 
Puma Biotechnology, Inc. 68 
Rhizen Pharmaceuticals S.A. 69 
Shionogi & Co., Ltd. 70 
Spectrum Pharmaceuticals, Inc. 71 
Symphogen A/S 72 
Taiho Pharmaceutical Co., Ltd. 73 
Taiwan Liposome Company, Ltd. 74 
Takara Bio Inc. 75 
Transgene Biotek Limited 76 
VioQuest Pharmaceuticals, Inc. 77 
XuanZhu Pharma Co., Ltd. 78 
Esophageal Cancer – Therapeutics Assessment 79 
Assessment by Monotherapy Products 79 
Assessment by Combination Products 80 
Assessment by Target 81 
Assessment by Mechanism of Action 86 
Assessment by Route of Administration 91 
Assessment by Molecule Type 93 
Drug Profiles 95 
(tipiracil hydrochloride + trifluridine) – Drug Profile 95 
1-BB1 – Drug Profile 101 
ADXS-HER2 – Drug Profile 102 
afatinib dimaleate – Drug Profile 106 
AL-3818 – Drug Profile 117 
ALM-301 – Drug Profile 119 
alpelisib – Drug Profile 120 
AMG-337 – Drug Profile 123 
apatinib – Drug Profile 125 
atezolizumab – Drug Profile 128 
ATL-101 – Drug Profile 141 
binimetinib – Drug Profile 143 
brontictuzumab – Drug Profile 150 
CDX-1401 – Drug Profile 153 
Cellular Immunotherapy for Oncology – Drug Profile 156 
Cellular Immunotherapy for Oncology – Drug Profile 157 
Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology – Drug Profile 158 
Cellular Immunotherapy to Target NY-ESO-1 for Oncology – Drug Profile 159 
cetuximab biobetter – Drug Profile 160 
CGX-1321 – Drug Profile 162 
CRLX-101 – Drug Profile 163 
CYC-140 – Drug Profile 174 
DKN-01 – Drug Profile 175 
donafenib – Drug Profile 177 
durvalumab – Drug Profile 178 
elgemtumab – Drug Profile 188 
erdafitinib – Drug Profile 190 
futuximab – Drug Profile 192 
ganetespib – Drug Profile 195 
gedatolisib – Drug Profile 207 
GSK-2256098 – Drug Profile 209 
GSK-3377794 – Drug Profile 211 
HMPL-309 – Drug Profile 217 
I131-CLR1404 – Drug Profile 218 
icotinib hydrochloride – Drug Profile 222 
IMF-001 – Drug Profile 224 
JS-001 – Drug Profile 225 
KML-001 – Drug Profile 226 
margetuximab – Drug Profile 228 
MBP-426 – Drug Profile 231 
miR-215 – Drug Profile 233 
MMD-37K – Drug Profile 234 
Monoclonal Antibodies to Inhibit PD-L2 for Esophageal Cancer – Drug Profile 235 
MVXONCO-1 – Drug Profile 236 
neratinib – Drug Profile 237 
nimotuzumab – Drug Profile 251 
nintedanib – Drug Profile 255 
nivolumab – Drug Profile 265 
OBP-301 – Drug Profile 295 
OMN-54 – Drug Profile 297 
paclitaxel albumin bound – Drug Profile 299 
panitumumab – Drug Profile 307 
pasireotide ER – Drug Profile 312 
PCA-062 – Drug Profile 315 
pembrolizumab – Drug Profile 316 
pralatrexate – Drug Profile 348 
RXDX-106 – Drug Profile 353 
S-222611 – Drug Profile 355 
S-588410 – Drug Profile 356 
sacituzumab – Drug Profile 358 
SDS-eCAR – Drug Profile 366 
sirotinib – Drug Profile 367 
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma – Drug Profile 368 
Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer – Drug Profile 369 
SMYD-2BAY02 – Drug Profile 370 
TBI-1201 – Drug Profile 371 
TBL-0805E – Drug Profile 373 
TGR-1202 – Drug Profile 374 
tiprelestat – Drug Profile 381 
tisotumab vedotin – Drug Profile 385 
tivantinib – Drug Profile 387 
TLC-388 – Drug Profile 393 
triciribine phosphate – Drug Profile 395 
Vaccine for Esophageal Cancer and Colorectal Cancer – Drug Profile 399 
varlitinib – Drug Profile 400 
YQ-23 – Drug Profile 403 
Esophageal Cancer – Dormant Projects 404 
Esophageal Cancer – Discontinued Products 409 
Esophageal Cancer – Product Development Milestones 410 
Featured News & Press Releases 410 
Appendix 423 
Methodology 423 
Coverage 423 
Secondary Research 423 
Primary Research 423 
Expert Panel Validation 423 
Contact Us 423 
Disclaimer 424

List of Tables 
Number of Products under Development for Esophageal Cancer, H2 2016 16 
Number of Products under Development for Esophageal Cancer – Comparative Analysis, H2 2016 17 
Number of Products under Development by Companies, H2 2016 18 
Number of Products under Development by Companies, H2 2016 (Contd..1) 19 
Number of Products under Development by Companies, H2 2016 (Contd..2) 20 
Number of Products under Development by Companies, H2 2016 (Contd..3) 21 
Number of Products under Investigation by Universities/Institutes, H2 2016 22 
Comparative Analysis by Late Stage Development, H2 2016 23 
Comparative Analysis by Clinical Stage Development, H2 2016 24 
Comparative Analysis by Early Stage Development, H2 2016 25 
Products under Development by Companies, H2 2016 26 
Products under Development by Companies, H2 2016 (Contd..1) 27 
Products under Development by Companies, H2 2016 (Contd..2) 28 
Products under Development by Companies, H2 2016 (Contd..3) 29 
Products under Development by Companies, H2 2016 (Contd..4) 30 
Products under Investigation by Universities/Institutes, H2 2016 31 
Esophageal Cancer – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 32 
Esophageal Cancer – Pipeline by Advaxis, Inc., H2 2016 33 
Esophageal Cancer – Pipeline by Advenchen Laboratories, LLC, H2 2016 34 
Esophageal Cancer – Pipeline by Almac Discovery Limited, H2 2016 35 
Esophageal Cancer – Pipeline by Amgen Inc., H2 2016 36 
Esophageal Cancer – Pipeline by ArQule, Inc., H2 2016 37 
Esophageal Cancer – Pipeline by Array BioPharma Inc., H2 2016 38 
Esophageal Cancer – Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2016 39 
Esophageal Cancer – Pipeline by ATLAB Pharma SAS, H2 2016 40 
Esophageal Cancer – Pipeline by Bayer AG, H2 2016 41 
Esophageal Cancer – Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016 42 
Esophageal Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 43 
Esophageal Cancer – Pipeline by Celgene Corporation, H2 2016 44 
Esophageal Cancer – Pipeline by Celldex Therapeutics, Inc., H2 2016 45 
Esophageal Cancer – Pipeline by Cellectar Biosciences, Inc., H2 2016 46 
Esophageal Cancer – Pipeline by Cerulean Pharma, Inc., H2 2016 47 
Esophageal Cancer – Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 48 
Esophageal Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 49 
Esophageal Cancer – Pipeline by Genmab A/S, H2 2016 50 
Esophageal Cancer – Pipeline by GlaxoSmithKline Plc, H2 2016 51 
Esophageal Cancer – Pipeline by Glycotope GmbH, H2 2016 52 
Esophageal Cancer – Pipeline by Hutchison MediPharma Limited, H2 2016 53 
Esophageal Cancer – Pipeline by Ignyta, Inc., H2 2016 54 
Esophageal Cancer – Pipeline by ImmunoFrontier, Inc., H2 2016 55 
Esophageal Cancer – Pipeline by Immunomedics, Inc., H2 2016 56 
Esophageal Cancer – Pipeline by Johnson & Johnson, H2 2016 57 
Esophageal Cancer – Pipeline by Komipharm International Co., Ltd., H2 2016 58 
Esophageal Cancer – Pipeline by MacroGenics, Inc., H2 2016 59 
Esophageal Cancer – Pipeline by MaxiVAX SA, H2 2016 60 
Esophageal Cancer – Pipeline by Mebiopharm Co., Ltd., H2 2016 61 
Esophageal Cancer – Pipeline by MedImmune, LLC, H2 2016 62 
Esophageal Cancer – Pipeline by Merck & Co., Inc., H2 2016 63 
Esophageal Cancer – Pipeline by Mirna Therapeutics, Inc., H2 2016 64 
Esophageal Cancer – Pipeline by Novartis AG, H2 2016 65 
Esophageal Cancer – Pipeline by Omeros Corporation, H2 2016 66 
Esophageal Cancer – Pipeline by Omnitura Therapeutics Inc., H2 2016 67 
Esophageal Cancer – Pipeline by Oncolys BioPharma Inc, H2 2016 68 
Esophageal Cancer – Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 69 
Esophageal Cancer – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 70 
Esophageal Cancer – Pipeline by Pfizer Inc., H2 2016 71 
Esophageal Cancer – Pipeline by Proteo, Inc., H2 2016 72 
Esophageal Cancer – Pipeline by Puma Biotechnology, Inc., H2 2016 73 
Esophageal Cancer – Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 74 
Esophageal Cancer – Pipeline by Shionogi & Co., Ltd., H2 2016 75 
Esophageal Cancer – Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 76 
Esophageal Cancer – Pipeline by Symphogen A/S, H2 2016 77 
Esophageal Cancer – Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 78 
Esophageal Cancer – Pipeline by Taiwan Liposome Company, Ltd., H2 2016 79 
Esophageal Cancer – Pipeline by Takara Bio Inc., H2 2016 80 
Esophageal Cancer – Pipeline by Transgene Biotek Limited, H2 2016 81 
Esophageal Cancer – Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016 82 
Esophageal Cancer – Pipeline by XuanZhu Pharma Co., Ltd., H2 2016 83 
Assessment by Monotherapy Products, H2 2016 84 
Assessment by Combination Products, H2 2016 85 
Number of Products by Stage and Target, H2 2016 87 
Number of Products by Stage and Mechanism of Action, H2 2016 92 
Number of Products by Stage and Route of Administration, H2 2016 97 
Number of Products by Stage and Molecule Type, H2 2016 99 
Esophageal Cancer – Dormant Projects, H2 2016 409 
Esophageal Cancer – Dormant Projects (Contd..1), H2 2016 410 
Esophageal Cancer – Dormant Projects (Contd..2), H2 2016 411 
Esophageal Cancer – Dormant Projects (Contd..3), H2 2016 412 
Esophageal Cancer – Dormant Projects (Contd..4), H2 2016 413 
Esophageal Cancer – Discontinued Products, H2 2016 414

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693289

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.